Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pancreas graft loss due to venous thrombosis is the leading non-immunological cause for graft failure following kidney-pancreas transplantation. Thromboelastography (TEG)-directed anticoagulation protocol has shown that approximately one-third of the patients undergoing pancreas transplantation require therapeutic anticoagulation to prevent the occurrence of graft thrombosis. This article presents the argument for individualised anticoagulation in these patients based on their TEG tracings and suggests the use of TEG in patients undergoing pancreas transplantation.

Original publication




Journal article


Clin Transplant

Publication Date





554 - 557


Anticoagulants, Female, Graft Occlusion, Vascular, Humans, Kidney Transplantation, Male, Pancreas Transplantation, Postoperative Care, Retrospective Studies, Thrombectomy, Thrombelastography, Thrombolytic Therapy, Treatment Outcome, Ultrasonography